183 related articles for article (PubMed ID: 36746437)
1. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Jing CB; Fu C; Prutsch N; Wang M; He S; Look AT
Leukemia; 2020 Nov; 34(11):2992-3006. PubMed ID: 32572188
[TBL] [Abstract][Full Text] [Related]
3. Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells.
McClatchy J; Strogantsev R; Wolfe E; Lin HY; Mohammadhosseini M; Davis BA; Eden C; Goldman D; Fleming WH; Conley P; Wu G; Cimmino L; Mohammed H; Agarwal A
Nat Commun; 2023 Dec; 14(1):8102. PubMed ID: 38062031
[TBL] [Abstract][Full Text] [Related]
4. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
5. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
[No Abstract] [Full Text] [Related]
6. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
7. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.
Cai Z; Kotzin JJ; Ramdas B; Chen S; Nelanuthala S; Palam LR; Pandey R; Mali RS; Liu Y; Kelley MR; Sandusky G; Mohseni M; Williams A; Henao-Mejia J; Kapur R
Cell Stem Cell; 2018 Dec; 23(6):833-849.e5. PubMed ID: 30526882
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
[TBL] [Abstract][Full Text] [Related]
10. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
Joshi K; Zhang L; Breslin S J P; Kini AR; Zhang J
J Exp Clin Cancer Res; 2022 Oct; 41(1):294. PubMed ID: 36203205
[TBL] [Abstract][Full Text] [Related]
11. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
[TBL] [Abstract][Full Text] [Related]
13. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
14. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
15. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
16. TET2 mutation as prototypic clonal hematopoiesis lesion.
Guarnera L; Jha BK
Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
[TBL] [Abstract][Full Text] [Related]
17. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
18. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.
Zhang Y; Yan X; Sashida G; Zhao X; Rao Y; Goyama S; Whitman SP; Zorko N; Bernot K; Conway RM; Witte D; Wang QF; Tenen DG; Xiao Z; Marcucci G; Mulloy JC; Grimes HL; Caligiuri MA; Huang G
Blood; 2012 Aug; 120(5):1118-29. PubMed ID: 22740449
[TBL] [Abstract][Full Text] [Related]
19. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
20. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
